Organogenesis Holdings Inc. (ORGO)

Market Cap	535.21M
Revenue (ttm)	482.04M
Net Income (ttm)	-937,000
Shares Out	126.83M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	105.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	626,939
Open	4.240
Previous Close	4.250
Day's Range	4.115 - 4.280
52-Week Range	2.165 - 6.710
Beta	1.80
Analysts	Buy
Price Target	5.50 (+30.64%)
Earnings Date	May 8, 2025

About ORGO

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic fo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 869
• Stock Exchange: NASDAQ
• Ticker Symbol: ORGO
• Website: https://organogenesis.com

Analyst Forecast

According to 2 analysts, the average rating for ORGO stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 30.64% from the latest price.

Price Target

$5.5

(30.64% upside)

Analyst Consensus: Buy